Contineum Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | — | $0 | $50.0M | — |
| Research and development | $51.5M | $38.4M | $27.6M | — |
| Operating expenses | $68.1M | $50.9M | $33.9M | — |
| Operating income | -$68.1M | -$50.9M | $16.1M | — |
| Interest expense | — | $0 | $208,000 | — |
| Pretax income | -$60.1M | -$42.3M | $23.2M | — |
| Income tax expense | $0 | $0 | $450,000 | — |
| Net income | -$60.0M | -$42.3M | $22.7M | — |
| Balance Sheet | ||||
| Cash and equivalents | $75.6M | $21.9M | $15.5M | — |
| Current assets | $267.9M | $206.4M | $127.7M | — |
| Total assets | $276.6M | $212.8M | $130.4M | — |
| Current liabilities | $9.7M | $10.0M | $5.5M | — |
| Total liabilities | $15.7M | $14.8M | $5.7M | — |
| Stockholders' equity | $261.0M | $198.1M | -$67.9M | -$93.2M |
| Cash Flow Statement | ||||
| Cash from operations | -$55.3M | -$32.8M | $19.3M | — |
| Depreciation and amortization | $323,000 | $258,000 | $195,000 | — |
| Stock-based compensation | $10.0M | $6.8M | $2.2M | — |
| Capital expenditure | $231,000 | $514,000 | $414,000 | — |
| Free cash flow | -$55.5M | -$33.4M | $18.9M | — |
| Share repurchases | — | $0 | $28,000 | — |
Shares outstanding 37.4M · Free float 85.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.